MRONJ and Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®)

Intra-operative Application of Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®) for the Surgical Treatment of Medication-related Osteonecrosis of the Jaws (MRONJ): a Pilot Study

Several circumstances or conditions, such as wound extension or disease, can affect the hard and soft tissue healing after surgical treatment of MRONJ. Supportive therapies are therefore needed to help tissues wound healing. The primary objective of this pilot clinical case series is to evaluate the post-operative wound healing in a group of patients undergoing surgical therapy for MRONJ with intraoperative application of a gel based on polynucleotides and hyaluronic acid (PN+HA) (Regenfast®)

Inclusion criteria:

• Patients older than 18 years
• Provided informed consent
• MRONJ stage 1 and stage 2 diagnosis, in accordance to SICMF-SIPMO classification
• Need to undergo surgical treatment of MRONJ

Exclusion criteria:

• Patients with history of head and neck radiotherapy
• Neurological and psychiatric conditions
• Pregnancy
• MRONJ stage 3 diagnosis
• Patients who will receive a re-treatment for MRONJ
• Patients with general contraindication for oral surgery
• Patients unable to attend the out-patients visits scheduled by the protocol